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Abstract
Background: Classic galactosemia is a rare genetic metabolic disease with an unmet treatment need. Current standard
of care fails to prevent chronically-debilitating brain and gonadal complications.
Many mutations in the GALT gene responsible for classic galactosemia have been described to give rise to variants with
conformational abnormalities. This pathogenic mechanism is highly amenable to a therapeutic strategy based on
chemical/pharmacological chaperones. Arginine, a chemical chaperone, has shown beneficial effect in other inherited
metabolic disorders, as well as in a prokaryotic model of classic galactosemia.
The p.Q188R mutation presents a high prevalence in the Caucasian population, making it a very clinically relevant
mutation. This mutation gives rise to a protein with lower conformational stability and lower catalytic activity. The
aim of this study is to assess the potential therapeutic role of arginine for this mutation.
Methods: Arginine aspartate administration to four patients with the p.Q188R/p.Q188R mutation, in vitro studies with
three fibroblast cell lines derived from classic galactosemia patients as well as recombinant protein experiments were
used to evaluate the effect of arginine in galactose metabolism. This study has been registered at https://clinicaltrials.
gov (NCT03580122) on 09 July 2018. Retrospectively registered.
Results: Following a month of arginine administration, patients did not show a significant improvement of whole-body
galactose oxidative capacity (p = 0.22), erythrocyte GALT activity (p = 0.87), urinary galactose (p = 0.52) and urinary
galactitol levels (p = 0.41). Patients’ fibroblasts exposed to arginine did not show changes in GALT activity. Thermal shift
analysis of recombinant p.Q188R GALT protein in the presence of arginine did not exhibit a positive effect.
Conclusions: This short pilot study in four patients homozygous for the p.Q188R/p.Q188R mutation reveals that arginine
has no potential therapeutic role for galactosemia patients homozygous for the p.Q188R mutation.
Keywords: Classic galactosemia, Inherited metabolic disorder, Galactose metabolism, Arginine, Amino acid
supplementation, Chemical chaperones
Background
Classic galactosemia (CG) (OMIM #230400) is a rare
metabolic disease caused by a severe deficiency of
galactose-1-phosphate uridylyltransferase (GALT), the sec-
ond enzyme of the main pathway for galactose metabolism.
It is an autosomal recessive disorder with a prevalence of
1:16,000 to 1:50,000 live births in Western countries.
Classic galactosemia represents a high burden in the
lives of patients and families [1]. Its current standard of
care, a galactose-restricted diet, even though life-saving
in the neonatal period, fails to prevent chronically-
debilitating complications, such as brain, gonadal and
social impairments. Brain complications result in cogni-
tive, behavioral and neurological complications. Patients
often achieve a lower grade of education and occupation,
they are often shy and less often succeed in building a
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relationship outside the family. More than 80% of female
patients suffer from primary ovarian insufficiency (POI)
with subsequently subfertility [2, 3]. Therefore, new
therapeutic strategies are needed.
Several mutations in the GALT gene have been de-
scribed to give rise to variants with a severely impaired
catalytic activity due to GALT misfolding and/or ag-
gregation in yeast and bacterial (E. coli) models [4, 5].
Notably, variant p.Q188R presented a strikingly high
aggregation propensity [5]. Recently, the crystal struc-
ture of human GALT was determined by McCorvie
et al. [6], providing a molecular framework to under-
stand disease-causing mutations at the protein level.
The c.563A > G (p.Q188R) mutation, the most
frequent GALT mutation in the Caucasian population
(> 60 to > 90% prevalence) [7] was described to give
raise to a protein with reduced conformational stabil-
ity and catalytic activity [6].
A promising therapeutic approach for conformational
disorders focuses on the use of chemical/pharmaco-
logical chaperones [8–10]. Arginine is a chemical
chaperone described to act as a selective inhibitor of un-
desirable protein aggregation [11, 12].
In vitro studies using a prokaryotic model of classic
galactosemia revealed that arginine might be of potential
value for a number of clinically-relevant mutations, in-
cluding p.Q188R [13].
Studies in fibroblasts from patients with a mild per-
oxisomal biogenesis disorder revealed that arginine
exerted a positive effect on the peroxisome function
[14]. More recently, Sorlin et al. described the case of
a patient with PEX12 deficiency that showed a posi-
tive effect at the biochemical and neurophysiological
levels following 12 months of treatment with arginine
[15]. Additionally, administration of arginine aspartate
(in the commercially available form of Asparten®) was
reported to have positive clinical and biochemical
effects in a patient with pyruvate dehydrogenase defi-
ciency (PDHc) [16].
The aims of this study were to evaluate the potential
therapeutic role of arginine in classic galactosemia
caused by the p.Q188R mutation.
Results
Arginine aspartate supplementation in patients
Four classic galactosemia patients homozygous for the
c.563A > G (p.Q188R) mutation were enrolled in the
clinical study. Patients’ characteristics are presented in
Table 1.
Assessments of the effect of arginine aspartate
supplementation (Asparten®) included whole body gal-
actose oxidative capacity (primary outcome), erythro-
cyte GALT activity, as well as urinary galactose and
galactitol levels (secondary outcomes). Baseline results
were obtained immediately before Asparten® supple-
mentation. Post treatment results were obtained after
30 ± 5 days of Asparten® intervention, immediately after
suspension of treatment.
No significant difference in the profile of mean galact-
ose oxidative capacity was observed (Fig. 1 and Add-
itional file 1: Figure S1). The CUMPCD (cumulative
percent of the dose) for the total time of the study (360
min) per patient is shown in Table 2. At baseline, the
mean 13CO2 released by the four patients was 2.8 ± 1.3%,
whereas after intervention it was 2.7 ± 1.2% (p = 0.22).
GALT activity before and after intervention is repre-
sented in Fig. 2. There was no statistically significant
(p = 0.87) increase in GALT activity following arginine
aspartate supplementation (baseline: 8.4 ± 2.2 μmol/h/
mmol Hb, corresponding to 1.5%; after treatment: 8.7 ±
4.9 μmol/h/mmol Hb, corresponding to 1.5%) (Table 2).
Mean urinary galactitol and galactose levels are shown
in Fig. 3. Both metabolites did not show a statistically
significant decrease after arginine aspartate supplemen-
tation. Galactitol decreased from 114 ± 16 to 110 ±
17 μmol/mmol creatinine (p = 0.41) (reference 0–
125 μmol/mmol creatinine) and galactose decreased
from 11 ± 9 to 7 ± 3 μmol/mmol creatinine (p = 0.52)
(Table 2).
Amino acid profile analysis revealed that plasma argin-
ine decreased from 67 ± 17 μmol/L at baseline to 53 ±
21 μmol/L following intervention (p = 0.05) (reference
16–124.9 μmol/L). Additionally, patients exhibited on
average an increase in plasma ornithine levels from 66 ±
25 μmol/mmol at baseline to 142 ± 73 μmol/L following
intervention (p = 0.07) (reference 24.0–167.9 μmol/L).
Other amino acids did not show any significant differ-
ence between baseline and after intervention.
The mean dietary arginine intake did not increase dur-
ing study (4 ± 1 g/day at baseline and after treatment)
(p = 0.87). Mean daily galactose intake did not change
during study period. All patients showed a high compli-
ance to Asparten® intake, ranging from 92 to 100%
(Table 2).
Patient 1 reported headache in the first two days of
Asparten® supplementation.
Arginine exposure of patients’ fibroblasts
In parallel with the clinical analysis, fibroblasts derived
from two p.Q188R/p.Q188R patients and one p.Q188R/
p.Q188P patient were cultured in the presence and
absence of arginine. GALT activity of exposed and unex-
posed fibroblasts is presented in Table 3. Patients’ fibro-
blasts displayed no detectable activity even in the
presence of a high concentration of arginine (1 mM). In
order to discard possible arginase activity, arginine in
the cell culture medium was measured. Results are pre-
sented in Additional file 2: Table S1.
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Thermal shift assay of recombinant human GALT in the
presence of arginine
The therapeutic benefit of arginine was previously
attributed to a possible role as chemical chaperone, stabil-
izing disease-associated proteins. To investigate this possi-
bility, the in vitro thermal shift assay (differential scanning
fluorimetry, DSF) was performed to evaluate whether
arginine could thermally stabilize recombinant GALT
(Table 4 and Fig. 4). Neither the p.Q188R or the wildtype
GALT protein showed a thermal shift in the presence
of arginine at any of the concentrations studied. In
contrast, galactose (10mM), a moiety of the substrate
galactose-1-phosphate, caused a small shift in the melting
temperature of the wildtype protein (ΔTm= 2.3 °C) but not
of the p.Q188R variant (ΔTm= 1.4 °C).
Discussion
In this study we evaluated the potential therapeutic role
of arginine in classic galactosemia caused by c.563A > G
(p.Q188R) mutation at three different levels: patients,
fibroblast galactosemic cell lines and recombinant
protein studies.
Patients were treated with arginine aspartate (in the
commercially available form of Asparten®) in a dose of
15 g/day for one month. Arginine aspartate supplemen-
tation (Asparten®) did not enhance galactose oxidation
rates or improve the biochemical profile in CG patients.
Whole body galactose oxidative capacity was evaluated
for 6 h (360 min) after administrating a bolus injection
of [1-13C]-galactose. The overall profile of galactose
oxidative capacity did not show an increase following
intervention (p = 0.22) (Fig. 1 and Additional file 1: Fig-
ure S1). All patients exhibited a CUMPCD less than 2%
at 120, before and after treatment, consistent with a se-
vere GALT deficiency, as described by Berry et al. [17].
GALT activity analysis in red blood cells (RBC)
revealed no statistically significant difference after treat-
ment compared to baseline. Galactose metabolite con-
centrations did not significantly change.
All patients continued with their galactose-restricted
diet, the lifelong mainstay of treatment in classic galac-
tosemia nowadays.
Amino acid profile analysis revealed that plasma
arginine decreased whereas ornithine levels increased. It
is known that arginase, the enzyme responsible for the
conversion of arginine into ornithine, exhibits an in-
creased transcription and activity upon exposure to
exogenous arginine [18], which very likely accounted for
the observed inverse plasmatic concentrations of these
amino acids.
No adverse events have ever been reported since
Asparten® entered in the market in 1974. In this study,
arginine was well tolerated, but patient 1 reported head-
ache in the first two days of Asparten® supplementation.
This could possibly be due to vasodilation caused by
nitric oxide production (NO) [19].
All patients showed a high compliance to Asparten®
(93 to 100%) which suggests that the observed lack of ef-
ficacy was not due to low adherence to intervention.
Dietary arginine intake was also evaluated due to its po-
tential to influence results. At baseline, the arginine
intake of patient 1 was nearly the double of that of the
other patients (92% higher) and after treatment it was
123% of that of the other patients, which might suggest
that increasing Asparten® administration would not
improve the biochemical phenotype. It is important to
keep in mind, however, that the metabolism of dietary
arginine and Asparten® supplementation might differ,
e.g. at the bioavailability level.
This is the first study to investigate the effect of
arginine aspartate (Asparten®) supplementation in classic
galactosemia. Asparten® has shown a positive effect in a
Table 1 Patients’ characteristics
Patient 1 Patient 2 Patient 3 Patient 4
Age (years) 29 21 19 24
Gender Male Female Male Female
Ethnicity Caucasian Caucasian Caucasian Caucasian
Genotype p.Q188R/p.Q188R p.Q188R/p.Q188R p.Q188R/p.Q188R p.Q188R/p.Q188R
Patients’ characteristics of the four classic galactosemia patients enrolled in the clinical study
Fig. 1 Mean galactose oxidative capacity before and after arginine
aspartate supplementation. Mean galactose oxidative capacity of the
four patients, expressed as CUMPCD (cumulative percent of the
dose) 13CO2 eliminated in air. Baseline: CUMPCD (120min) = 0.7 ±
0.06%; CUMPCD (360 min) = 2.8 ± 1.3%. After intervention: CUMPCD
(120 min) = 0.7 ± 0.02%; CUMPCD (360 min) = 2.7 ± 1.2%
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PDHc deficient patient [16]. After 1 month of Asparten®
administration, the 6-year-old patient showed a striking
improvement on both biochemical and clinical out-
comes. The patient was on a daily dose of 5 g arginine
aspartate (Asparten®). In the present study, the adult
patients were on a daily dose of 15 g arginine aspartate
(Asparten®). However, Asparten® did not ameliorate the
biochemical phenotype of the studied patients.
These findings contradict the previous study on the
prokaryotic model of galactosemia, in which arginine
supplementation to the medium in a concentration of
25 mM partially rescued the bacterial culture expressing
human GALT p.Q188R [13]. These discrepancies might
stem from the high arginine concentration used in the
prokaryotic model.
Limitations of this study are the small number of subjects
and relatively short duration of Asparten® supplementation.
With respect to the RBC GALT activity, the lifespan of
erythrocytes is about 120 days, both in galactosemic and in
non-galactosemic patients. Since the study was conducted
for 1 month, the effect of Asparten® on the GALT activity
could be underestimated [20, 21]. The short duration of the
study was also insufficient to evaluate Asparten® effects on
long-term clinical outcomes. Furthermore, younger patients
could have responded differently to Asparten®‘s treatment.
However, neither fibroblast assays nor in vitro studies using
recombinant human p.Q188R GALT showed a positive
effect, which suggests that arginine’s mechanism of action as
a chemical chaperone is not effective for this GALT variant.
These findings do not preclude that arginine could be
successfully used in patients carrying other GALT muta-
tions that lead to a conformational change without irre-
versibly affecting the catalytic activity. Further studies
are warranted to gain more insight in arginine’s potential
effect on other less frequent GALT mutations.
Recently, the crystallographic structure of human
GALT has been reported [6], and will contribute for
the development of GALT-based therapeutic ap-
proaches, namely pharmacological chaperones (PCs).
PCs are a promising therapeutic approach in protein
misfolding diseases. PCs bind specifically to the target
protein and shift the equilibrium towards the correctly
folded state of the protein. A number of pharmaco-
logical chaperones has been successfully developed in
the field of inherited metabolic disorders (reviewed in
ref. [10, 22]). Arginine is a chemical chaperone de-
scribed to act as a selective inhibitor of undesirable
protein aggregation [11, 12].
Table 2 Primary and secondary outcomes of the clinical study
Patient 1 Patient 2 Patient 3 Patient 4
Baseline After
treatment
Baseline After
treatment
Baseline After
treatment
Baseline After
treatment
CUMPCD 13CO2 at 360 min (%)
a 2.5 2.6 2.8 2.8 2.9 2.6 3.0 2.7
GALT activity (μmol/h/mmol Hb) 6.7 (1.2%) 6.1 (1.1%) 11.3 (2.0%) 16.0 (2.8%) 8.8 (1.5%) 5.7 (1.0%) 6.9 (1.2%) 6.9 (1.2%)
Galactitol in urine (μmol/mmol creatinine) 115 123 132 123 114 106 93 87
Galactose in urine (μmol/mmol creatinine) 6 11 5 6 8 5 24 7
Dietary arginine intake (g/day) 6 6 4 3 4 4 3 4
Compliance to Asparten ® (%) 100 93 92 98
Days of treatment 28 28 35 35
Supplementation of arginine aspartate (Asparten®) was evaluated by whole body galactose oxidative capacity (primary outcome), erythrocyte GALT activity, as
well as urinary galactose and galactitol levels (secondary outcomes). Baseline evaluation was done immediately before the initiation of Asparten®
supplementation, after treatment evaluation was done immediately after suspension of Asparten® supplementation
a CUMPCD (cumulative percent of the dose) 13CO2 eliminated in air at 360 min
Fig. 2 Mean GALT activity before and after arginine aspartate
supplementation. GALT activity is expressed as μmol of UDP-Gal
formed per hour per mmol hemoglobin
Fig. 3 Mean urinary galactitol and galactose levels before and after
arginine aspartate supplementation
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The new knowledge and understanding gained with
the human GALT crystal structure holds great prom-
ise for the development of a PC-based therapeutic
approach for CG. Furthermore, the crystal structure
will also guide other developments of therapies for
this disease, besides the PC-based approach. Other
therapeutic approaches include substrate reduction
therapies by GALK1-inhibitors, superoxide dismutase
and enzyme replacement therapy to increase the ac-
tivity of human GALT.
Conclusion
In conclusion, the results of this pilot study suggest that
neither arginine nor arginine aspartate (Asparten®)
would be therapeutically effective in galactosemia pa-
tients homozygous for the c.563A > G (p.Q188R) muta-
tion under the presented conditions. Nevertheless, these
findings do not preclude that arginine could be success-
fully used in patients carrying other GALT mutations.
Further studies are warranted to gain more insight in ar-
ginine’s effect on other GALT mutations.
Patients and methods
Patients
Four adult classic galactosemia patients being followed
up in our expertise centrum for classic galactosemia car-
rying the p.Q188R mutation in homozygosity were
included in the study (Table 1). Written informed
consent was obtained from all patients participating in
the study. The study was approved by the Medical Eth-
ical Committee of the Maastricht University Medical
Center + (METC). This study has been registered at
https://clinicaltrials.gov (NCT03580122).
Study design and intervention
This is a study with a pre-post single arm design. All
patients received arginine in the commercially available
form of arginine aspartate (Asparten®). This formula was
chosen based on the fact that it is administered by oral
route and it displays well-known pharmacokinetic and
toxicological characteristics. It is commercialized since
1974 and no side effects have ever been described. Each
ampoule of Asparten® contains 5 g of arginine aspartate.
Following the screening and baseline assessments, patients
received 5 g of arginine aspartate, 3 times a day (as recom-
mended in Asparten®‘s Summary of Product Characteris-
tics), corresponding to a daily dose of 15 g arginine
aspartate. Duration of the intervention was 1month (30 ±
5 days). Patients were asked to keep the empty ampoules in
order to ascertain compliance to intervention.
Diet
All patients remained on a galactose-restricted diet,
which consists of eliminating all galactose- and
lactose-containing dairy products from the diet (except
for mature cheeses and caseinates); non-dairy sources
of galactose, such as fruit and vegetables are allowed.
Patients were asked to keep a 3-day diary of their diet
in the beginning and in the end of the study to be able
to calculate the average arginine intake.
Assessments
All patients were evaluated at baseline and after
intervention. Primary outcome was whole body galactose
oxidative capacity. Secondary outcomes included
erythrocyte GALT activity, as well as urinary galactose
and galactitol levels. Additionally, pre-prandial amino
acid profile was also performed.
Baseline assessments were done immediately before
the initiation of Asparten® supplementation, and after
treatment assessments were done immediately after sus-
pension of Asparten® supplementation.
Primary outcome
Whole body galactose in vivo oxidative capacity was de-
termined as previously described [17, 23]. Patients were
administered 7 mg/kg [1-13C]-galactose tracer (0.039
mmol/kg, Cambridge Isotope Laboratories, Andover,
USA) via a single bolus injection. Expired breath samples
were collected into 10 mL Exetainer tubes (Labco
limited, Lampeter, UK), which were filled directly from a
mixing chamber in duplicate. A baseline breath sample
Table 3 GALT enzymatic activity in fibroblasts exposed to
arginine
GALT activity (μmol/h/g protein)
Cell line No arginine 0.1 mM arginine 1 mM arginine
Control 1 (n = 3) 31.6 ± 12.9 45.6 ± 25.1 35.3 ± 21.3
Control 2 (n = 2) 52.9 46.1 42.9
CG 1 (n = 2) n.d. n.d. n.d.
CG 2 (n = 2) n.d. n.d. n.d.
CG 3 (n = 2) n.d. n.d. n.d.
Two wildtype (controls 1 and 2) and three classic galactosemic fibroblasts
derived from two p.Q188R/p.Q188R patients (cell lines CG1 and CG2) and a
p.Q188R/p.Q188P patient (cell line CG3) were cultured in the absence and in
the presence of supplemental arginine (0.1 mM and 1mM arginine). Results
are expressed as μmol per hour per gram protein and presented as mean ± SD
or average for n = 2. Number of replicates is presented in brackets
n.d.: non-detectable
Table 4 Thermal shift assay of wildtype and p.Q188R GALT
Melting temperature (Tm, °C)
Wildtype GALT p.Q188R GALT
None 55.8 ± 0.2 54.6 ± 0.2
Arginine 54.8 ± 0.1 54.7 ± 0.4
Galactose 58.1 ± 0.4 56.0 ± 0.3
Comparison of temperature at which half the protein was unfolded (melting
temperature, Tm) with no added ligand, arginine (10 mM) or galactose (10
mM). Values presented are the mean values of three replicates
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was collected prior to [1-13C]-galactose injection (t = 0
min). During the first hour following injection, breath
samples were collected at t = 5, 15, 30, 45 and 60min.
Thereafter, breath samples were collected at 30-min in-
tervals until t = 360min. Whole-body oxygen uptake
(VO2) and carbon dioxide (VCO2) production were
measured during three 60min periods (t = 30–90, 150–
210, and 270–330 min) using a ventilated hood system
(Omnical, Maastricht University, Maastricht, the
Netherlands). During the entire study period, subjects
rested supine and were allowed to drink only water.
Expired breath samples were analyzed for 13C/12C ra-
tio by gas chromatograph continuous flow isotope
ratio mass spectrometry (Finnigan, Bremen, Germany).
The isotopic enrichment was expressed as δ per mil
difference between the 13C/12C ratio of the sample and
a known laboratory reference standard [24].
The δ13C was then related to an international
standard (PDB-1). The 13CO2 production from the
oxidation of the infused [1-13C]-galactose tracer was
subsequently calculated as:
Pr13CO2 ¼ TTRCO2 x VCO2ð Þkð Þ
Where TTRCO2 is the breath
13C/12C ratio at a
given time point, VCO2 is the carbon dioxide pro-
duction (L∙min− 1), k is the volume of CO2 (22.4
L∙mol− 1). Total 13CO2 production represents a minimal
estimate of the total amount of [1-13C]-galactose that was
oxidized within the experimental period. In addition,
the cumulative percent of the [1-13C]-galactose tracer
eliminated as 13CO2 in expired air (CUMPCD) was
calculated.
Secondary outcomes
GALT enzymatic activity in RBC was performed as pre-
viously described [25]. Galactose and galactitol levels
were measured in urine by GC/MS.
Amino acid profile was measured as described by
Waterval et al. [26].
Diet
Dietary intake of arginine was determined by a 3-day
food diary pre and post intervention and calculated as
mean percentage of the total protein intake. The amount
of arginine was considered to be 5% of the total protein
intake [27].
Fibroblasts
Cultured fibroblasts from two wildtype and three
classic galactosemic patients (Coriell GM1703, GM727
with p.Q188R/p.Q188R mutations and a Boston
Children’s Hospital patient with p.Q188R/p.Q188P
mutations) were grown in MEM media supplemented
with 10% FBS at a 37 °C incubator with humidified at-
mosphere of 5% CO2. Arginine treatment was started
by supplementing the growth media with 0, 0.1 mM or
1.0 mM of arginine (considered as day 0 of arginine
treatment). On day 3 of the arginine treatment, cells
were washed with ice cold PBS and pellets were har-
vested in cold PBS by scraping. The pellets were
stored in − 80 °C until enzyme measurements. The
GALT activity in cell lysates was measured using
LC-MS/MS by a modified version of a method previ-
ously described for washed RBC [28]. Cell lysates were
prepared by resuspending the pellets in 100–200 μL
0.5 M glycine buffer (pH 8.7) and sonicating for 15 s at
level 1 (Sonic Dismembrator model 100, Fisher Scien-
tific, USA) three times with one-minute intervals. The
homogenate was then centrifuged at 15,800 g for 10
min at 4 °C (5402R, Eppendorf ). Protein concentration
was quantified using DC kit (Bio-RAD). AB Sciex
QTrap 5500 mass spectrometer was used for quantifi-
cation of the enzyme product. Arginine was measured
in the cell culture supernatant by stable isotope
dilution liquid chromatography tandem mass spec-
trometry (LC-MS/MS) using a 15N-L-Arginine internal
standard (Cambridge Isotope Laboratories Inc.,
Tewksbury, MA, USA) with an Acquity™ Ultraperfor-
mance® liquid chromatography system coupled to a
Quattro Premier tandem-quadrupole mass spectrom-
eter (Waters Corporation, Milford, MA, USA).
Fig. 4 Representative thermal shift assay curves with no added ligand, arginine (10 mM) or galactose (10 mM) for A. wildtype GALT and B.
p.Q188R GALT. Fluorescence values were normalized to allow comparison of Tm values. Curves for single replicate per ligand state plotted, with
no added ligand, arginine (10 mM) or galactose (10 mM). Values stated are the mean values of three replicates
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Recombinant protein analysis
Expression and purification of human GALT was per-
formed as previously described [6]. Differential scanning
fluorimetry (DSF) was performed in a 96-well plate using
an Mx3005p RT-PCR machine (Stratagene) with excitation
and emission filters of 492 and 610 nm, respectively. Each
20 μL reaction consisted of 2 μL as-purified recombinant
protein (final concentration of 2 μM, wildtype or p.Q188R)
and 2 μL arginine at various concentrations (100 μM to 10
mM) in DSF buffer (150mM NaCl, 10mM HEPES pH 7.5)
to which 2 μL SYPROrange, diluted 500-fold in DSF buffer
from the manufacturer’s stock (Invitrogen) was added. Gal-
actose (10mM) was used as an indicator of ligand binding
(positive control). Fluorescence intensities were measured
at each 1 °C temperature increase from 25 to 96 °C with a
ramp rate of 3 °C/min. A thermal shift of 3 °C or more is
considered to be significant, though interpretation varies,
and some papers report a value > 1.5 °C as significant.
Statistical analysis
Arginine aspartate’s effect in the primary and secondary
outcomes was evaluated in IBM SPSS Statistics 23, using
a paired t-test (double-sided) with a natural correction
for non-normal populations. A p value less than 0.05
was considered statistically significant.
Additional files
Additional file 1: Figure S1. Expired breath 13CO2 enrichments.
Expired breath 13CO2 enrichments of the four galactosemia patients,
before and after arginine aspartate supplementation. Results are
expressed as mean ± SEM. (PDF 95 kb)
Additional file 2: Table S1. Concentration of arginine in the cell culture
supernatant. The concentration of arginine was measured at day 0 and 3 of
incubation in two wildtype (Control line 1 and 2) and two classic galactosemic
fibroblasts derived from two p.Q188R/p.Q188R patients (cell lines CG1 and
CG2) in the absence and in the presence of supplemental arginine (0.1mM
and 1mM arginine). Results are expressed as μM. (PDF 16 kb)
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